Background-We tested the hypothesis that increased cardiac myocyte adenylyl cyclase (AC) content increases cardiac function and response to catecholamines in cardiomyopathy. Methods and Results-Transgenic mice with cardiac-directed expression of AC type VI (AC VI ) were crossbred with mice with cardiomyopathy induced by cardiac-directed G q expression. G q mice had dilated left ventricles, reduced heart function, decreased cardiac responsiveness to catecholamine stimulation, and impaired ␤-adrenergic receptor (␤AR)-dependent and AC-dependent cAMP production. G q /AC mice showed improved basal cardiac function in vivo (Pϭ0.01) and ex vivo (PϽ0.0005). When stimulated through the ␤AR, cardiac responsiveness was increased (Pϭ0.02), and cardiac myocytes showed increased cAMP production in response to isoproterenol (Pϭ0.03) and forskolin (PϽ0.0001). Key Words: receptors, adrenergic, beta Ⅲ gene therapy A hallmark of dilated cardiomyopathy is decreased generation of cAMP by cardiac myocytes in response to ␤-adrenergic receptor (␤AR) stimulation. However, treatments for clinical heart failure that increase myocardial cAMP content with pharmacological agents that stimulate the ␤AR or decrease the breakdown of cAMP generally have failed, perhaps because of deleterious consequences of unrelenting stimulation of the ␤AR. Indeed, overexpression of cardiac ␤ARs in transgenic mice caused increased basal heart rate, function, and cAMP generation, 1 and mice overexpressing cardiac G s␣ developed cardiomyopathy due to sustained ␤AR stimulation. 2 Cardiac-directed overexpression of ␤ARs failed to improve heart function and increased mortality in murine dilated cardiomyopathy. 3 We recently showed that cardiac myocytes with increased expression of adenylyl cyclase (AC) produce more cAMP when stimulated through the ␤AR or AC. 4 Cardiac-directed expression of AC type VI (AC VI ) results in a phenotypically normal heart with normal basal function and cAMP levels but supranormal responses to catecholamine stimulation. 5 Thus, receptor/G-protein overexpression and standard inotropic therapy yield continuous ␤AR activation and detrimental consequences, whereas overexpression of cardiac AC VI alters transmembrane signaling only when receptors are activated.
A hallmark of dilated cardiomyopathy is decreased generation of cAMP by cardiac myocytes in response to ␤-adrenergic receptor (␤AR) stimulation. However, treatments for clinical heart failure that increase myocardial cAMP content with pharmacological agents that stimulate the ␤AR or decrease the breakdown of cAMP generally have failed, perhaps because of deleterious consequences of unrelenting stimulation of the ␤AR. Indeed, overexpression of cardiac ␤ARs in transgenic mice caused increased basal heart rate, function, and cAMP generation, 1 and mice overexpressing cardiac G s␣ developed cardiomyopathy due to sustained ␤AR stimulation. 2 Cardiac-directed overexpression of ␤ARs failed to improve heart function and increased mortality in murine dilated cardiomyopathy. 3 We recently showed that cardiac myocytes with increased expression of adenylyl cyclase (AC) produce more cAMP when stimulated through the ␤AR or AC. 4 Cardiac-directed expression of AC type VI (AC VI ) results in a phenotypically normal heart with normal basal function and cAMP levels but supranormal responses to catecholamine stimulation. 5 Thus, receptor/G-protein overexpression and standard inotropic therapy yield continuous ␤AR activation and detrimental consequences, whereas overexpression of cardiac AC VI alters transmembrane signaling only when receptors are activated.
This could provide increased cAMP generation in heart failure in a manner that circumvents the deleterious consequences of sustained activation.
Cardiac-directed expression of G q results in reduced left ventricular (LV) function, decreased cardiac responsiveness to catecholamines, and impaired ␤AR-dependent and ACdependent cAMP production. 6 The exact mechanism for dilation is unknown, but G q is coupled to endothelin, angiotensin II, and ␣ 1 -adrenergic receptors, pathways that influence cardiac myocyte growth and remodeling. This model provides an opportunity to test the hypothesis that cardiacdirected AC expression can increase cAMP generation and restore heart function and response to catecholamines in dilated cardiomyopathy.
Methods

Animals
Animal use followed institutional guidelines. Generation of mice with cardiac-directed expression of murine AC VI was described recently, 5 as was cardiac-directed G q -induced cardiomyopathy. 6 G q -40 (FVB/N) mice, which show increased G q protein expression and impaired systolic function compared with G q -25 mice, 6 were crossbred with AC VI (CB6) mice; transgene-negative siblings served as controls. Mice were studied at 15Ϯ4 weeks (range, 10 to 20 weeks). Transmural LV samples were fixed with formalin, sectioned, and stained with hematoxylin and eosin and with Masson's trichrome.
Documentation of Transgene Expression
Gene presence and expression was documented with polymerase chain reaction (not shown) and immunoblotting of cardiac homogenates with antibodies recognizing AC VI and G q (Santa Cruz Biosciences) (Figure 1 ). 4, 5 
Echocardiography
Animals were anesthetized with intraperitoneal injection of ketamine (50 g/g) and thiobutabarbital (50 to 100 g/g) and studied as previously described. 5 Additional images were obtained after intraperitoneal injection of dobutamine (4 g/g).
Ex Vivo Heart Function
Cardiac function in response to adrenergic stimulation was assessed in isolated perfused hearts (paced at 400 bpm, end-diastolic pressure 10 mm Hg) with an intraventricular balloon catheter to measure isovolumic LV pressure (previously described 6 ). Dobutamine (0.001 to 100 mol/L) was delivered in bolus doses at 5-minute intervals as LV pressure was recorded.
Isolation of Cardiac Myocytes and cAMP Generation
Ventricular myocytes were isolated. 5 Equal numbers of viable cardiac myocytes were incubated (10 minutes, 25°C) in fresh DMEM containing no addition (basal), 10 mol/L isoproterenol, or 10 mol/L forskolin. Intracellular cAMP levels were determined by radioimmunoassay (Amersham Life Science). 
Myocardial
Results
Transgenic Mice
We obtained substantial cardiac-directed expression of AC VI and G q in the G q /AC group and increased expression of G q in the G q line (Figure 1 ). The Table shows group characteristics. Litter sizes were normal, and mortality was invariant among the groups. LV histology showed no abnormalities.
Echocardiography
Basal and dobutamine-stimulated fractional shortening were reduced in the G q mice. Concurrent expression of AC (G q /AC) increased basal (Pϭ0.01) and dobutamine- stimulated (Pϭ0.02) fractional shortening toward normal (Figure 2a ). G q mice had reduced heart rates, as previously reported, 6 and concurrent AC expression (G q /AC) increased heart rate toward normal (Table) . End-diastolic diameter was increased by G q expression and unaffected by concurrent AC expression (Table) . Wall thickness was invariant between groups (not shown).
Ex Vivo Heart Function
Concurrent expression of AC increased peak positive (PϽ0.0005; Figure 2b ) and peak negative LV dP/dt (PϽ0.04), indicating increased rates of LV contractility and relaxation compared with G q mice.
Transmembrane ␤AR Signaling G q mice showed reduced cardiac myocyte cAMP production, and concurrent AC expression (G q /AC) increased cAMP production in response to isoproterenol (Pϭ0.03) and forskolin (PϽ0.0001) (Figure 2c and 2d) . Radioligand binding assays and immunoblotting indicated that ␤AR density and the contents of G proteins and GRK2 were unchanged (Table) .
Discussion
We asked whether increased AC expression could favorably affect heart function in cardiomyopathy. Our data indicate that AC expression restores cAMP-generating capacity, improves basal heart function, and increases the heart's response to ␤AR stimulation. These favorable effects did not decay over a broad age range (10 to 20 weeks), and hearts of AC/G q mice showed no histological abnormalities. We have previously shown the safety and persistent favorable effects of life-long cardiac-directed AC expression. 5 The mechanism for impaired ␤AR responsiveness in G q cardiomyopathy is unknown but is associated with impaired cAMP production in cardiac membranes and a dilated poorly functioning heart, features that establish this as an apt model of clinical dilated cardiomyopathy, in which similar findings are present. Increasing cardiac ␤AR expression and inhibition of GRK function have been examined as therapeutic interventions for heart failure. 3 However, overexpression of the ␤AR worsened outcomes when concurrently expressed in murine cardiomyopathy and inhibition of GRK function completely prevented the development of cardiomyopathy. 3 The persistence of chamber enlargement in the G q /AC line, despite marked improvement in cardiac function and cAMP generation, is consonant with a treated condition. Had AC VI reversed this defect, one could infer that AC VI had simply prevented the heart failure phenotype from ever developing. Our data indicate the underlying cardiomyopathy is present but that the function of this diseased heart is substantially improved.
Are these findings relevant to the treatment of clinical dilated cardiomyopathy? The G q cardiomyopathy model does not exhibit myocardial ␤AR downregulation, as seen in clinical heart failure. However, like failed human hearts, this model shows chamber enlargement, impaired systolic function, and diminished responsiveness to ␤AR stimulation in vivo, as well as decreased production of cAMP with ␤AR stimulation.
There are varying reports regarding whether forskolinstimulated cAMP production is reduced in failing human myocardium, 7, 8 but a consistent finding is reduced ␤AR-stimulated cAMP generation, 7 a finding that is also present in G q cardiomyopathy. 6 Overexpression of AC increases ␤AR-stimulated cAMP production even when ␤AR number and coupling and endogenous AC function and amount are normal. 4, 5 These data indicate that AC sets a limit on transmembrane ␤AR signaling in the heart and that increasing AC content is likely to increase transmembrane signaling independently of the endogenous amounts of ␤AR and AC.
Overexpression of the ␤AR, Gs␣, or the use of inotropic drugs 9 provides perpetual adrenergic activation with dire consequences. In contrast, AC overexpression provides increased recruitable adrenergic responsiveness without sustained adrenergic activation. This provides a rational potential therapeutic option for clinical dilated cardiomyopathy. In conclusion, increased cardiac AC content improves heart function and responsiveness to ␤AR stimulation in the setting of cardiomyopathy. This is associated with a restored ability of cardiac myocytes to generate cAMP in response to adrenergic stimulation. Five animals per group. d, Cardiac myocyte cAMP production: AC stimulation. Cardiac myocytes were stimulated by 10 mol/L forskolin, and cAMP was measured. cAMP production differed between groups (Pϭ0.001, ANOVA). Cardiac myocyte cAMP production was reduced in the G q mice; concurrent expression of AC (G q /AC) increased cAMP production (PϽ0.0001). Five animals per group.
